DiaMedica Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.7%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.83next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| ReMEDy2 AIS Trial Interim Analysis Completion | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
ReMEDy2 Trial Enrollment Progress Quarterly75.0Target: 100% of 200-patient interim threshold
Cash and Short-Term Investments Quarterly51.3MTarget: Sufficient to fund operations through 2027
Quarterly Net Cash Used in Operating Activities Quarterly9.1MTarget: Maintain cash runway through 2027
Watch Items
- ReMEDy2 Phase 2/3 AIS Trial Interim AnalysisTrigger: Completion of Day 90 follow-up for the first 200 patientsAction: Independent DSMB review to recommend sample size re-estimation (300 to 728 patients) or stop for futility.
- DM199 Preeclampsia Nonclinical Rat PK and Activity StudyTrigger: Demonstration of sufficient drug exposure and enzymatic activity in ratsAction: Conduct a rat pharmacokinetic (PK) and pharmacologic activity study to demonstrate sufficient evidence of DM199 exposure, enzymatic activity, and pharmacologic effect in rats to support their use as an appropriate toxicology species.
- Phase 2 DM199 Early-Onset Preeclampsia Study Site ActivationTrigger: Commencement of site activation in Canada and the United KingdomAction: Initiate patient enrollment in Canada and file a clinical trial application (CTA) in the UK.
Research as of 19 Jun 2026